Article

Osteoporosis Study Suggests Bone Density Testing Intervals for Older Women

Osteoporosis would develop in fewer than 10% of older, postmenopausal women during rescreening intervals of about 15 years for those with normal bone density or mild osteopenia, 5 years for those with moderate osteopenia, and 1 year for those with advanced osteopenia, according to a study reported in The New England Journal of Medicine.

Osteoporosis would develop in fewer than 10% of older, postmenopausal women during rescreening intervals of about 15 years for those with normal bone density or mild osteopenia, 5 years for those with moderate osteopenia, and 1 year for those with advanced osteopenia, according to a study reported in The New England Journal of Medicine. Noting that there are few data to guide decisions about the interval between bone mineral density (BMD) tests, Gourlay and colleagues1 at the University of North Carolina, Chapel Hill, studied 4957 women, aged 67 years and older, who had normal BMD or osteopenia and no history of hip or clinical vertebral fracture or of treatment for osteoporosis. The BMD testing interval was defined as the estimated time for 10% of women to make the transition to osteoporosis before having a hip or clinical vertebral fracture, with adjustment for estrogen use and clinical risk factors.

The estimated BMD testing interval was 16.8 years for women with normal BMD, 17.3 years for women with mild osteopenia, 4.7 years for women with moderate osteopenia, and 1.1 years for women with advanced osteopenia. The authors suggested that the baseline T score is the most important determinant of a BMD testing interval.

(Listen to an interview with the lead author of the study about how to judge appropriate intervals for bone density testing among women in your practice.)

References:

References

1. Gourlay ML, Fine JP, Preisser JS, et al; Study of Osteoporotic Fractures Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366:225-233.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.